Life Sciences Bioavailability, Bioequivalence

Proving the bioavailability/bioequivalence of a drug candidate with reliable data, on-time and on budget, is a cornerstone for generic companies. With biological drugs now making up a large proportion of new drugs, this poses new challenges to generic companies as their “biosimilars” cannot be seen as true generics.

Why choose bioavailability/bioequivalence clinical trials from SGS?

We provide you with:

A highly beneficial regulatory environment in Belgium, enabling a fast study start within two to three weeks from dossier submission to first subject screened

With over 35 years of experience in early clinical trials, and unmatched Phase 1 expertise, we have the resources and facilities to deliver your bioavailability/bioequivalence clinical trials quickly and accurately.

Contact us today to discuss how we can help with your bioavailability/bioequivalence and biosimilar clinical trials.